Literature DB >> 956809

In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.

R D Johnson, C R Ruthven, B L Goodwin, M Sandler.   

Abstract

In the L-Dopa treated rat, a decreased urinary output of free and conjugated dopamine and an increase in free and conjugated L-Dopa excretion after administration of decarboxylase-inhibiting drugs provide a good in vivo index of Dopa decarboxylase inhibition. With the exception of free dopamine output, which showed an equivocal change, these measurements appear to provide a good yardstick of decarboxylase status in man also. Using this approach, it was not possible to find any evidence of facilitation of decarboxylase action, in L-Dopa-treated parkinsonians given pyridoxine supplements, to account for the ability of this compound to neutralize the beneficial effect of L-Dopa.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956809     DOI: 10.1007/BF01249438

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  25 in total

1.  Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA.

Authors:  C C PORTER; L S WATSON; D C TITUS; J A TOTARO; S S BYER
Journal:  Biochem Pharmacol       Date:  1962-11       Impact factor: 5.858

2.  Decreased 5-hydroxytryptophan decarboxylase activity in phenylketonuria.

Authors:  C M PARE; M SANDLER; R S STACEY
Journal:  Lancet       Date:  1958-11-22       Impact factor: 79.321

3.  Role of L-DOPA decarboxylase in the biosynthesis of catecholamines in nervous tissue and the adrenal medulla.

Authors:  P HOLTZ
Journal:  Pharmacol Rev       Date:  1959-06       Impact factor: 25.468

4.  Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase.

Authors:  G Bartholini; W P Burkard; A Pletscher
Journal:  Nature       Date:  1967-08-19       Impact factor: 49.962

5.  Sulphate conjugation and L-dopa treatment of Parkinsonian patients.

Authors:  C O Rutledge; M M Hoehn
Journal:  Nature       Date:  1973-08-17       Impact factor: 49.962

6.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

7.  Gas chromatographic measurement of urinary catecholamines by an electron capture detection procedure.

Authors:  K P Wong; C R Ruthven; M Sandler
Journal:  Clin Chim Acta       Date:  1973-08-30       Impact factor: 3.786

8.  The quantitative assessment of isoprenaline metabolism in man.

Authors:  C D Morgan; C R Ruthven; M Sandler
Journal:  Clin Chim Acta       Date:  1969-12       Impact factor: 3.786

9.  Pyridoxine reversal of L-dopa effects in Parkinsonism.

Authors:  R C Duvoisin; M D Yahr; L D Coté
Journal:  Trans Am Neurol Assoc       Date:  1969

10.  Occurrence and distribution of L-DOPA decarboxylase in the human brain.

Authors:  K Lloyd; O Hornykiewicz
Journal:  Brain Res       Date:  1970-09-16       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.